Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Neoplasms: ENETS Center of Excellence Experience

#2836

Introduction: There is a substantial clinical unmet need for an accurate blood biomarker for neuroendocrine neoplasms (NENs).

Aim(s): Evaluate, under real-world conditions, the clinical utility of the NETest as a liquid biopsy in an ENETS Center of Excellence and compare with chromogranin A (CgA).

Materials and methods: Cohorts: GEPNENs [253] (pancreatic [83], ileal/jejunal [54], duodenal [12], gastric [46], rectal [46], appendiceal [12]), BPNENs [68], colon cancer [37], NSCLC [63], benign lung disease [59] and normal controls [86]. Two-hundred and eleven NENs had detectable disease, these comprised: G1 [106], G2 [49], G3 [9], TC [14], AC [14], SCLC [15] and LCNEC [4]. Disease status (stable [SD] or progressive [PD]) determined by RECIST 1.1. NETest (n=566) and NETest/CgA matched samples (n=182). Statistical analysis: Kruskal-Wallis or Mann-Whitney U-test, McNemar’s test. Data: mean±SEM.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Malczewska A

Authors: Malczewska A, Witkowska M, Wojcik-Giertuga M, Bocian A, Walter A,

Keywords: NETest, liquid biopsy, neuroendocrine, GEP-NEN, BPNEN, CgA, biomarker,